Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EYE National Vision	$25.34 -0.5%	$22.39	$9.56 ▼ $25.67	$2.01B	1.27	2.15 million shs	1.10 million shs
LMAT LeMaitre Vascular	$80.77 -1.7%	$82.64	$71.42 ▼ $109.58	$1.86B	0.82	112,976 shs	102,061 shs
NVCR NovoCure	$12.54 -24.0%	$17.40	$12.46 ▼ $34.13	$1.84B	0.72	1.08 million shs	5.33 million shs
SMLR Semler Scientific	$38.89 -1.1%	$38.68	$21.77 ▼ $81.56	$542.16M	1.39	808,585 shs	539,251 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EYE National Vision	+1.96%	+0.55%	+12.30%	+109.37%	+91.58%
LMAT LeMaitre Vascular	+2.20%	-0.54%	-1.46%	-10.46%	-8.77%
NVCR NovoCure	+1.29%	-0.48%	-0.60%	-11.00%	-12.04%
SMLR Semler Scientific	-2.16%	-7.94%	-6.36%	+14.17%	+15.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EYE National Vision	2.8177 of 5 stars	2.3	2.0	0.0	3.3	2.8	0.8	0.0
LMAT LeMaitre Vascular	2.7232 of 5 stars	2.2	1.0	3.3	0.0	2.7	2.5	1.3
NVCR NovoCure	3.7908 of 5 stars	3.4	1.0	0.0	4.5	3.3	1.7	0.0
SMLR Semler Scientific	3.2969 of 5 stars	3.7	2.0	0.0	0.0	2.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EYE National Vision	2.56	Moderate Buy	$23.00	-9.23% Downside
LMAT LeMaitre Vascular	2.33	Hold	$97.83	21.13% Upside
NVCR NovoCure	2.71	Moderate Buy	$32.43	158.60% Upside
SMLR Semler Scientific	3.33	Buy	$89.00	128.85% Upside

Current Analyst Ratings Breakdown

Latest SMLR, EYE, LMAT, and NVCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/23/2025	EYE National Vision	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $24.00
7/22/2025	LMAT LeMaitre Vascular	Barrington Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
7/9/2025	SMLR Semler Scientific	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$95.00
7/8/2025	EYE National Vision	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/8/2025	EYE National Vision	National Bankshares Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$30.00
7/8/2025	EYE National Vision	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$17.00 ➝ $30.00
7/8/2025	NVCR NovoCure	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
7/8/2025	SMLR Semler Scientific	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$101.00
6/27/2025	NVCR NovoCure	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$34.00
6/18/2025	EYE National Vision	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
5/19/2025	EYE National Vision	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Market Perform ➝ Market Perform	$13.00 ➝ $19.00

(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EYE National Vision	$1.82B	1.10	$1.63 per share	15.58	$10.37 per share	2.44
LMAT LeMaitre Vascular	$219.86M	8.30	$2.35 per share	34.40	$15.00 per share	5.38
NVCR NovoCure	$605.22M	2.31	N/A	N/A	$3.33 per share	3.77
SMLR Semler Scientific	$56.29M	9.53	$4.42 per share	8.79	$24.90 per share	1.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EYE National Vision	-$28.50M	-$0.33	N/A	93.85	3.74	-1.40%	3.44%	1.40%	8/6/2025 (Estimated)
LMAT LeMaitre Vascular	$44.04M	$1.98	40.79	37.22	2.17	19.96%	13.53%	9.78%	8/5/2025 (Estimated)
NVCR NovoCure	-$168.63M	-$1.51	N/A	N/A	N/A	-26.41%	-45.46%	-13.34%	7/24/2025 (Estimated)
SMLR Semler Scientific	$40.90M	-$2.61	N/A	∞	N/A	-60.69%	19.75%	15.47%	8/4/2025 (Estimated)

Latest SMLR, EYE, LMAT, and NVCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	EYE National Vision	$0.12	N/A	N/A	N/A	$469.21 million	N/A
8/5/2025	Q2 2025	LMAT LeMaitre Vascular	$0.57	N/A	N/A	N/A	$62.48 million	N/A
7/24/2025	Q2 2025	NVCR NovoCure	-$0.39	-$0.36	+$0.03	-$0.36	$153.87 million	N/A
5/13/2025	Q1 2025	SMLR Semler Scientific	N/A	-$0.76	N/A	-$6.74	N/A	$8.84 million
5/7/2025	Q1 2025	EYE National Vision	$0.32	$0.34	+$0.02	$0.18	$510.30 million	$510.32 million
5/1/2025	Q1 2025	LMAT LeMaitre Vascular	$0.50	$0.48	-$0.02	$0.48	$57.61 million	$59.87 million
4/24/2025	Q1 2025	NVCR NovoCure	-$0.47	-$0.31	+$0.16	-$0.31	$147.57 million	$154.99 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EYE National Vision	N/A	N/A	N/A	N/A	N/A
LMAT LeMaitre Vascular	$0.80	0.99%	N/A	40.40%	14 Years
NVCR NovoCure	N/A	N/A	N/A	N/A	N/A
SMLR Semler Scientific	N/A	N/A	N/A	N/A	N/A

Latest SMLR, EYE, LMAT, and NVCR Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2025	LMAT LeMaitre Vascular	quarterly	$0.20	1%	5/15/2025	5/15/2025	5/29/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EYE National Vision	0.29	0.54	0.35
LMAT LeMaitre Vascular	0.48	16.49	13.83
NVCR NovoCure	0.27	1.47	1.41
SMLR Semler Scientific	0.59	0.52	0.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EYE National Vision	N/A
LMAT LeMaitre Vascular	84.64%
NVCR NovoCure	84.61%
SMLR Semler Scientific	49.37%

Insider Ownership

Company	Insider Ownership
EYE National Vision	2.70%
LMAT LeMaitre Vascular	9.50%
NVCR NovoCure	5.52%
SMLR Semler Scientific	30.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EYE National Vision	13,411	79.05 million	76.92 million	Optionable
LMAT LeMaitre Vascular	490	22.59 million	20.45 million	Optionable
NVCR NovoCure	1,488	111.49 million	105.33 million	Optionable
SMLR Semler Scientific	120	13.79 million	9.62 million	Not Optionable

SMLR, EYE, LMAT, and NVCR Headlines

Recent News About These Companies

Semler Scientific Purchases 175 BTC and Launches Public Bitcoin Dashboard

July 24 at 4:18 PM | bitcoinmagazine.com

Semler Scientific Acquires Bitcoin Worth Over $20 Million, Total Holdings Cross 5,000 BTC

July 24 at 11:17 AM | msn.com

Semler Scientific® Announces Earnings Release Date and Live Video Webinar for Second Quarter 2025 Financial Results

July 21 at 5:48 PM | prnewswire.com

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

July 20, 2025 | globenewswire.com

Principal Financial Group Inc. Sells 55,102 Shares of Semler Scientific Inc. (NASDAQ:SMLR)

July 19, 2025 | marketbeat.com

Rosen Law Firm Encourages Semler Scientific, Inc. Investors to Inquire About Securities Class Action Investigation - SMLR

July 18, 2025 | prnewswire.com

Semler Scientific Advances to 14th-Largest Public Bitcoin Holder Following $25 Million Investment

July 18, 2025 | coinspeaker.com

Semler Scientific Becomes 14th-Largest Public Bitcoin Holder After $25M BTC Buy

July 18, 2025 | finance.yahoo.com

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

July 17, 2025 | globenewswire.com

9,970 Shares in Semler Scientific Inc. (NASDAQ:SMLR) Purchased by Alps Advisors Inc.

July 16, 2025 | marketbeat.com

Semler Scientific (NASDAQ:SMLR) Trading Down 8.2% - Here's What Happened

July 15, 2025 | marketbeat.com

135 Public Companies That Hold Bitcoin — And Why It Matters

July 15, 2025 | schaeffersresearch.com

Semler Scientific: Still A Cheap Proxy For Bitcoin's Surge

July 14, 2025 | seekingalpha.com

Semler Scientific Inc (SMLR) - Investing.com

July 12, 2025 | investing.com

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

July 11, 2025 | globenewswire.com

Semler Scientific (NASDAQ:SMLR) Stock Price Up 8% - Here's What Happened

July 10, 2025 | marketbeat.com

Maxim Group Initiates Coverage of Semler Scientific (SMLR) with Buy Recommendation

July 10, 2025 | msn.com

Semler Scientific Stock Gets Relative Strength Rating Upgrade

July 9, 2025 | msn.com

Semler Scientific (NASDAQ:SMLR) Now Covered by Maxim Group

July 9, 2025 | marketbeat.com

Benchmark Initiates Coverage of Semler Scientific (SMLR) with Buy Recommendation

July 9, 2025 | msn.com

SMLR Investor News: If You Have Suffered Losses in Semler Scientific, Inc. (NASDAQ: SMLR), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

July 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
By Dan Schmidt | July 2, 2025
View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous Revolution
Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
By Ryan Hasson | July 1, 2025
View Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside
3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
By Chris Markoch | July 14, 2025
View 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge
By Chris Markoch | June 27, 2025
View Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge
2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
By Leo Miller | July 18, 2025
View 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban

SMLR, EYE, LMAT, and NVCR Company Descriptions

National Vision NASDAQ:EYE

$25.34 -0.14 (-0.55%)

Closing price 04:00 PM Eastern

Extended Trading

$25.77 +0.43 (+1.70%)

As of 05:50 PM Eastern

National Vision Holdings, Inc., through its subsidiaries, operates as an optical retailer in the United States. The company operates in two segments, Owned & Host and Legacy. It offers eyeglasses and contact lenses, and optical accessory products; provides eye exams through its America's Best, Eyeglass World, Vista Optical, Fred Meyer, and Vista Optical military, as well as Vision Center branded stores; and offers health maintenance organization and optometric services. National Vision Holdings, Inc. was founded in 1990 and is headquartered in Duluth, Georgia.

LeMaitre Vascular NASDAQ:LMAT

$80.77 -1.39 (-1.69%)

Closing price 04:00 PM Eastern

Extended Trading

$80.83 +0.06 (+0.08%)

As of 04:10 PM Eastern

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

NovoCure NASDAQ:NVCR

$12.54 -3.97 (-24.05%)

Closing price 04:00 PM Eastern

Extended Trading

$12.69 +0.15 (+1.19%)

As of 07:59 PM Eastern

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Semler Scientific NASDAQ:SMLR

$38.89 -0.43 (-1.09%)

Closing price 04:00 PM Eastern

Extended Trading

$38.52 -0.37 (-0.94%)

As of 07:56 PM Eastern

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time